In contrast, we retrospectively analyzed clinical and molecular variables beyond common factors like age, Karnofsky performance status (KPS), isocitrate dehydrogenase (IDH) mutation, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for a prognostic model regarding OS in patients with recurrent gliomas arising from primary tumors of different grades who received various BEV-containing regimens at Peking Union Medical College Hospital (PUMCH). The gene discussed is MGMT; the disease is glioma.